IL-15 has been actively investigated for its potential in tumor immunotherapy. To enhance the anti-tumor activity of IL-15, BJ-001, an integrin targeting IL-15 was designed and studied. B-J001 showed tumor cell targeting without compromising IL-15 activity in vivo. In xenograft models, BJ-001 had potent anti-tumor activities. For majority of immunotherapies, increased efficacy is associated with increased toxicity. Interestingly, by monitoring the changes of immune cells and cytokines in vivo, the toxicity and efficacy of BJ-001 can be uncoupled. Increased efficacy of BJ-001 can be achieved without increasing toxicity. These studies may provide guidance for the therapeutic use of BJ-001, which is currently in Phase I human trial.

Citation Format: Yanlan Wang, Ziyan Zhu, Meng Zhang. Decouple the toxicity and efficacy of BJ-001, an integrin targeting IL-15 [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr LB-A21. doi:10.1158/1535-7163.TARG-19-LB-A21